Current practice and future directions in CSA treatment: positive airway pressure, stimulation and pharmacotherapy

M. Arzt (Regensburg, Germany)

Source: Sleep and Breathing Conference 2021
Session: Current knowledge and research priorities in central sleep apnoea
Session type: Symposium
Number: 0

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Arzt (Regensburg, Germany). Current practice and future directions in CSA treatment: positive airway pressure, stimulation and pharmacotherapy. Sleep and Breathing Conference 2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Therapeutic approaches beyond positive airway pressure and bronchodilators: time for rehabilitation?
Source: Sleep and Breathing Conference 2021
Year: 2021


Defining the core components of a clinical review of people using continuous positive airway pressure (CPAP) therapy - an international e-Delphi study
Source: International Congress 2018 – Sleep and breathing control: phenotypes
Year: 2018

A new UK approach in the management of patients on continuous positive airway pressure (CPAP) therapy
Source: Eur Respir J 2003; 22: Suppl. 45, 96s
Year: 2003

Airway inflammation in asthma: current and future targets and therapies
Source: Breathe 2010; 6: 245-252
Year: 2010

Impact of an educational intervention to improve adherence to treatment with continuous pressure airway positive
Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology
Year: 2012


Rethinking the way we are treating established airway disease: current guidelines need to change 
Source: International Congress 2016 – Presentation and discussion of a draft Lancet Commission on Asthma
Year: 2016


Measuring airway hyperresponsiveness: does it add to routine measures of clinical efficacy in guiding asthma therapy?
Source: Eur Respir J 2006; 28: Suppl. 50, 319s
Year: 2006

Does consultation with a sleep medicine specialist improve patient compliance with nasal continuous positive airway pressure therapy?
Source: Eur Respir J 2002; 20: Suppl. 38, 474s
Year: 2002

Future directions: preventing and treating asthma
Source: International Congress 2016 – Childhood wheeze: are we making any progress?
Year: 2016


Targeting airway inflammation in asthma: current and future therapies
Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment
Year: 2009



Targeting airway inflammation in asthma: current and future therapies
Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies
Year: 2009


Effectiveness of different models of maintenance therapy for bronchial asthma (BA) in routine clinical practice
Source: Eur Respir J 2007; 30: Suppl. 51, 70s
Year: 2007

New and future developments of therapy for asthma in children
Source: Eur Respir Mon 2012; 56: 224-234
Year: 2012


Current developments and future directions in respiratory physiotherapy
Source: Eur Respir Rev, 29 (158) 200264; 10.1183/16000617.0264-2020
Year: 2020



Treatment of interstitial lung diseases: current approaches and future directions
Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options
Year: 2021


Pharmacological options for the treatment of COPD: present and future
Source: Annual Congress 2007 - PG6 - COPD: comprehensive clinical assessment and pharmacological and nonpharmacological therapy
Year: 2007

Filling the gaps: future treatment options for mild asthma
Source: International Congress 2018 – The complexities of managing mild asthma
Year: 2018

Fixed CPAP versus other positive pressure modes: theory, facts and perspectives
Source: Annual Congress 2008 - Practical workshop: Compliance to nasal continuous positive airway pressure: what makes the difference?
Year: 2008


Dose-FEV1 modeling to support future development of AZD2115, a dual acting bronchodilator for the treatment of COPD
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015